about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Pas­sive vac­ci­na­tion? As­traZeneca spot­lights six-month pro­tec­tion with Covid-19 an­ti­body among vul­ner­a­ble group

4 years ago
R&D
Coronavirus

Covid-19 pill could add an­oth­er $15-25B to Pfiz­er's al­ready tor­rid pan­dem­ic cash flow — an­a­lyst

4 years ago
Coronavirus

In wake of PhII flop, Roche walks away from $350M Covid-19 an­tivi­ral pact

4 years ago
Deals
Coronavirus

Out to prove the next big I/O tar­get, Im­mu­ni­tas' chief deal­mak­er steps up to CEO role

4 years ago
People
R&D

As­traZeneca, Mod­er­na start to raise the cur­tain on a new mR­NA heart drug — but ef­fi­ca­cy will have to wait

4 years ago
R&D
Cell/Gene Tx

Reel­ing from PD-1 slap­down, In­cyte stirs con­cerns with side ef­fects of oral PD-L1 — al­though drug is al­so 'clear­ly ...

4 years ago
R&D

J&J's im­pend­ing split; And the next FDA com­mish is...; Aduhelm back in spot­light; #AHA21; and more

4 years ago
Weekly

As­traZeneca ex­pects 'mod­est prof­itabil­i­ty' for next round of Covid-19 vac­cine sup­ply deals — and prunes pipeline in ...

4 years ago
R&D
Pharma

It’s Califf: Biden picks the for­mer FDA com­mish to head back to the helm

4 years ago
People
FDA+

On the heels of sol­id tu­mor da­ta and with com­peti­tors surg­ing, Po­sei­da scraps au­tol­o­gous CAR-T in fa­vor of al­lo

4 years ago
R&D
Cell/Gene Tx

Pfiz­er wa­gers $1.2B on Bio­haven's lead mi­graine drug — and picks up a next-gen can­di­date — as mar­ket­ing wars heat ...

4 years ago
Deals

Low-pro­file eye drop de­vel­op­er spells out the game plan that drew Brent Saun­ders to the board — and it in­volves ...

4 years ago
Financing

'We were wrong': Af­ter ush­er­ing Mer­ck KGaA in­to PD-(L)1 fren­zy, on­col­o­gy chief jumps on mis­sion to 'tur­bocharge' T ...

4 years ago
Financing
Cell/Gene Tx

Steer­ing clear of Fi­bro­Gen/As­traZeneca wreck­age, Glax­o­SmithK­line spot­lights piv­otal da­ta for star ane­mia drug

4 years ago
R&D

Pfiz­er's Covid pill de­liv­ers; All you need to know about Dem­s' drug pric­ing plan; What else can an­ti­sense do?; and ...

4 years ago
Weekly

Tout­ing close ties to biotech in­cu­ba­tors, Mis­sion Bio­Cap­i­tal grabs $275M to help launch star­tups

4 years ago
Financing

No­var­tis signs off on $20B deal to sell Roche stake, ac­quired 20 years ago, back to cross-town ri­val

4 years ago
Deals

Am­gen spot­lights pre­clin­i­cal 'mul­ti-specific­s' as an­a­lyst pre­dicts late-stage M&A

4 years ago
R&D

Lead­ing pro­teomics play­er gets a trio of new part­ners; GV tries to pre­vent cer­vi­cal can­cer

4 years ago
News Briefing

As an­ti-in­flam­ma­to­ry space heats up, Pfiz­er spins JAK, TYK2 drugs in­to new start­up

4 years ago
Deals

No­var­tis en­lists transat­lantic start­up to dis­cov­er new pro­tein de­graders in $1.3B+ deal

4 years ago
Deals

FDA push­es back de­ci­sion on J&J, Leg­end's BC­MA CAR-T

4 years ago
Cell/Gene Tx
FDA+

Per­cep­tive steers Lian­Bio's glob­al­ly con­nect­ed Chi­na strat­e­gy to $325M IPO

4 years ago
Financing
China

FDA safe­ty re­view to hold up Mod­er­na’s Covid-19 vac­cine for teens un­til 2022

4 years ago
FDA+
Coronavirus
First page Previous page 41424344454647 Next page Last page
A service from the Financial Times